Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A clinical trial to test whether Azithromycin, a commonly used antibiotic, can treat the symptoms of COVID-19 in outpatients has recruited its first patient.

Azithromycin package © www.doctor-4-u.co.uk/ via Flickr

The ATOMIC2 trial is being led from Oxford with support from the Oxford Clinical Trials Research Unit (OCTRU) at NDORMS. It will enrol 800 people who are being assessed at hospital with COVID-19 but felt well enough to be cared for at home. Half will receive Azithromycin for two weeks, while the rest will get regular care. Participants will also give samples of blood and samples from the nose so researchers can better understand the biology of the virus.

The trial will take place across 15 sites across England, Wales and Scotland. It complements two other national trials – RECOVERY and PRINCIPLE – which are testing Azithromycin in different categories of patients.

The trial's Chief Investigator is Dr Tim Hinks of the University of Oxford's Nuffield Department of Medicine and an Oxford BRC Senior Fellow. He said: "Azithromycin is an antibiotic with unusual anti-inflammatory and anti-viral properties, so it is being seen as a promising potential treatment for COVID-19.

In COVID-19 patients, there is a window of opportunity of about two weeks when the disease progresses from mild symptoms, such as fatigue, fever and cough, to severe respiratory failure.

Azithromycin is safe, inexpensive and available worldwide, so if effective, it could be a very useful weapon in the fight against this pandemic. And even if we find that the drug is not effective against the symptoms of COVID-19, it is still an important finding."

Azithromycin, or AZM, is widely used to tackle a wide range of infections, such as trachoma, a cause of blindness, genital infections, pneumonias, multidrug resistant tuberculosis and a wide range of inflammatory lung diseases and viruses, and so it's important it is only used where really effective to prevent development of antibiotic resistance.
It also has additional antibacterial properties which may help prevent secondary bacterial infection, present in 16 percent of COVID-19 deaths.

The trial has received funding from the NIHR Oxford Biomedical Research Centre (BRC), as well as the University of Oxford and Pfizer.

 

Similar stories

Patient and public involvement in Rheumatology research – embracing the wave of change

On launching the new OPEN ARMS PPI group in Oxford, Dr. Laura Coates explored the patient and public involvement (PPI) models of three academic centres in the UK to show how it benefits researchers, clinicians, and patients alike.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

NDORMS joins research partnership to understand links between overlapping long-term conditions

The links between different long-term health conditions will be explored in new research funded with a £2.5million grant from the Medical Research Council.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Researchers show the role of cilia in cartilage health

New research shows that disrupting primary cilia in juvenile, adolescent and early adulthood in cartilage stops it maturing correctly, making it more prone to thinning and the potential for osteoarthritis (OA) in later life.

SCIENCE spreads across the world

Oxford Trauma are pleased to open their first overseas site for the SCIENCE study.